-The Hindu Doctors’ objections to prescribing medicines by generic names fly in the face of a recent report on substandard drugs In a surprise move on April 17, Prime Minister Narendra Modi announced that his government will soon make it mandatory for doctors to prescribe medicines by generic names. The decision was to ensure drug prices remain affordable and patients get a wider bouquet of options instead of being forced to...

-The Telegraph New Delhi: Supreme Court advocate Prashant Bhushan today urged environment minister Anil Dave to reject a regulatory panel's recommendation to release genetically modified mustard for commercial cultivation, questioning the regulatory process and claims about the plant's superiority. In a letter to Dave, Bhushan cited a Supreme Court hearing on GM crops and described India's regulatory mechanisms for such crops as "farcical". He asked Dave to "withhold" his approval to the...

-The Times of India NEW DELHI: The government announced on Friday that 'Janaushadhi' stores will be opened in every block to make low-priced generic medicines available across the country. The scheme is expected to create a "silent revolution" in achieving health security by providing affordable and quality medicines for all. Union minister for chemicals & fertilizers Ananth Kumar said the government plans to open such stores so that doctors and pharmacists cannot push...

-The Hindu The core issues are affordable access to medicines and their rational prescription and use The Medical Council of India (MCI) issued a circular on April 21 drawing attention to clause 1.5 of its regulations regarding the professional conduct of doctors: “Every physician should prescribe drugs with generic names legibly and preferably in capital letters and he/she shall ensure that there is a rational prescription of drugs.” Further, the circular said,...

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism...